GENFLEET-B (02595) has announced the initiation of a three-arm, parallel-controlled Phase II clinical study evaluating GFH375, an oral KRAS G12D ON/OFF inhibitor. The trial will assess two novel combination regimens against single-agent therapy in patients with KRAS G12D-mutated, previously treated locally advanced unresectable or metastatic pancreatic cancer.
This multicenter, open-label, randomized controlled study will be conducted across dozens of sites in mainland China, with Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital serving as the lead center. The two combination strategies under investigation include GFH375 plus GFS202A, the world's first cachexia bispecific antibody targeting GDF15/IL-6, and GFH375 combined with GFH276, a pan-RAS ON inhibitor.
In February 2026, GFH375/VS-7575 was the first to receive breakthrough therapy designation in China for single-agent treatment of KRAS G12D-mutated metastatic pancreatic cancer, following a fast-track designation granted by the U.S. FDA in 2025 for KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma (PDAC). KRAS G12D mutations occur in approximately 40% of pancreatic cancer patients, while the incidence of cachexia in this population exceeds 60%, the highest among all tumor types.
A recent Nature feature highlighted the current treatment landscape for pancreatic cancer patients with cachexia, referencing the CANCAN (Cancer Cachexia Action Network) observational study—initiated by the U.S. National Cancer Institute and Cancer Research UK—which enrolled nearly a thousand cancer patients. The article revealed associations between elevated GDF15 levels and tumor progression and cachexia, with multiple preclinical studies demonstrating that increased GDF15 can aberrantly link pathological signaling among tumors, the immune system, and the brain, contributing to weight loss and treatment intolerance. Additionally, elevated IL-6 levels were shown to reduce dopamine release, thereby suppressing feeding and behavioral drive in mice.
Clinical data from overseas trials combining GDF15 or IL-6 monoclonal antibodies with standard-of-care therapy in PDAC suggest significant improvements in patient body composition and treatment tolerance, as well as enhanced anti-tumor efficacy and overall survival. The combination of a KRAS G12D inhibitor with cachexia therapy is expected to produce mechanistic synergy. GFH375 has already entered the world's first registrational Phase III study of an oral KRAS G12D inhibitor as monotherapy for metastatic pancreatic cancer. Preliminary data for GFS202A were selected for presentation at the 2026 ASCO Annual Meeting poster session, demonstrating favorable safety and therapeutic potential, including appetite improvement and dose-dependent increases in body weight and skeletal muscle mass.
Furthermore, combining selective and pan-RAS inhibitors is anticipated to achieve deeper, more durable tumor responses and delay resistance emergence in clinical practice. Preclinical studies conducted by GENFLEET's R&D team in KRAS G12D-mutated PDAC animal models showed that the GFH375 and GFH276 combination produced synergistic anti-tumor effects surpassing either monotherapy. In the overseas RAS landscape, Revolution Medicines has initiated clinical trials combining its molecular glue KRAS G12D inhibitor (RMC-9805) with a pan-RAS inhibitor (RMC-6236) in PDAC, with preliminary data presented at the 2026 EMSO GI conference demonstrating objective response rates superior to single-agent therapy.
Comments